Main Article

With a projected growth rate of 12 percent to $5.6 billion this year, the molecular diagnostic market in the United States remains robust, but the current recession and tight capital market pose significant challenges for both labs and diagnostic test manufacturers, said industry experts at the Washington G-2 Reports’ Molecular Diagnostic 2009, held February 2 to 4, in Fort Lauderdale, Fla.

Subscribers: click here for the full story

Non-Subscribers: click here to subscribe

March 2009 - Table of Contents

LIR March 2009 (full PDF issue)

G-2 Predicts Mol Dx Testing to Grow 12% in 2009 to $5.6 Billion in Favorable Pricing Environment

Esoteric Business Drives LabCorp’s FY2008 Revenue Up 10% to $4.5 Billion, Q408 Revenue Up 11.3% to $1.1 Billion

Sonic’s Acquisition Strategy Drives Revenue Up 28% to $938M for First Half FY2009; U.S. Organic Revenue Up 6%

Bio-Reference Courier System Improvements Boosts Efficiency, Sees Seven Month ROI

Inside the Lab Industry: Mol Dx Labs and Manufacturers Confront Tight Capital Market

Aurora Diagnostics’s Revenue Up Over 100% to $150 Million in 2008

DTC Advertising, Sales Effort Expansion Drives Myriad’s Q2 Revenues Up 58% for Q209

Response Genetics Consolidates Operations by Shuttering U.K. Operation

Lab Stocks Experience Uptick in February; Up 10% Over 13 Weeks

Industry Buzz: Bostwick Laboratories Launches Hematopath Division, Names Medical Director